Measuring bursting strength is the standard method for evaluating mosquito net strength. However, in real life use scenarios of nets these are rarely exposed to the kind of strain they are exposed to in this test. It would correspond to, more or less, if you were to grab on to a net by the hands, uniformly and without penetrating the mesh with your fingers, and pull the net apart. Few people can do that. However, if you put the netting on a nail at one end and pull with your hand at the other, a hole will be ripped with very little effort.
Most of us that have worked in the field of malaria for a few decades have gone through periods where we suddenly noticed changes in drug policy. When chloroquine was replaced by sulfadoxine-pyremethamine as a first-line drug, later to be replaced by artemisinin combination therapies (ACTs).
But the world is now faced with a new challenge. That of preventing artemisinin resistance from escaping south-east Asia. Without anything to replace it (yet), this is a looming catastrophe, according to Joel Breman in an interview with TropIKA.net. It may still be confined to the Thai-Cambodia border, although nobody really nows have far it has spread.
The article below was contributed by journalist Leocadia Bongben (Cameroon) as part of the SjCOOP project in collaboration with MalariaWorld.
An international alliance of malaria scientists, whose secretariat has roved around the planet until now, is planning to settle down permanently in Yaoundé.
The Multilateral Initiative for Malaria (MIM), established in 1997, was previously headquartered in London, Washington, Stockholm and Dar es Salaam.
Even when treated with the best anti-malaria drugs 1 in 5 children with cerebral malaria will die, and of the survivors 1 in 4 will be left with long-term learning and memory impairment. This is because the host response to the infection plays as much a role in contributing to the development of cerebral malaria as does the parasite itself. Although conventional therapies for malaria can be very effective at eliminating the parasite, they do little to modulate the host response.
The use of entomopathogenic fungi as a means to control populations of adult malaria vectors is gaining increased attention. Recently we reported on the PhD thesis of Dr. Marit Farenhorst, and below we report the findings from the PhD of Dr. Joel Mouatcho, who recently graduated from the University of Witwatersrand in South Africa.
The treatment of malaria has been hampered by the appearance of parasites resistant to conventional malaria drugs. Disease progression relies on the adherence of parasite-containing red blood cells to the blood vessel tissues. This condition allows the parasite to evade its clearance from the blood. Current treatments focus on killing the parasites inside of infected red blood cells but resistant strains have evolved with the ability to pump the drugs out of the erythrocytes.
Although ACTs are recommended as first line treatment for uncomplicated malaria, actual use of ACT is very limited, partly due to its high price in pharmacies and retail stores. The Affordable Medicines Facility-malaria (AMFm), a donor-funded global price subsidy, has been proposed as a strategy to increase ACT use in malaria-endemic countries. Given that donor-supported ACT subsidy schemes are costly, it is crucial to ensure that they have their intended impact.
My name is Dave Richard and I’m a new investigator based at the Centre de Recherche en Infectiologie du CHUL, Université Laval, in Quebec City, Canada.
I am establishing this Blog in the hopes of stimulating interest in improving the WHO and PMI strategies for fighting malaria in Africa.
For most part my colleagues Stella, Kabogo and I are often holed up in Malaria World, Nairobi office digging through hundreds of journals to pick out anything relevant to the “Malaria World”. Over the past weeks we have held discussions of what really happens out there, how is the war against malaria coming along? Are we loosing or winning?